Finance

What will current stranglehold mean for industry down the line?

Genomic data is transforming precision medicine—but progress depends on it being easily available where it’s needed. Pharmaceutical Executive speaks to Ignacio Medina, founder of Cambridge University spinout Zetta Genomics, to see how next-generation open-source data technologies accelerate discovery in the lab and patient benefit in the clinic.

Full-year business review of pharma and biotech sectors reveals strong momentum in advancing novel science and treatments, but likely foretells continued stock instability in near-to-medium terms.

But a doubling-down on R&D offers reason for optimism.

Biopharma stock performance continues to struggle.

Brief summary of EY’s 2022 M&A Firepower report highlights trends.

Ahead of the release of EY’s annual M&A Firepower report this week, Pharm Exec talks to EY’s Arda Ural to review biopharma M&A activity in 2021 and to discuss the likely deal drivers of 2022.

Christopher J. Calhoun pulls back the curtain on the mysterious biotech funding process.

Industry growth in innovation could spark financial rebound.

Regulatory headwinds are poised to ease as new year approaches.

While Q3 numbers look bleak, is improvement on the horizon?

Though M&A activity and equity market outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable—driven by R&D gains, record IPO levels.

With large M&A deals comes a complex Market Authorization Transfer (MAT) process, during which regulatory teams must weigh several operational aspects while creating a roadmap that takes them into account. Cecile Riboud outlines some key questions that are necessary for planning and executing a successful MAT process.

But could there be a shift in momentum?

Biopharma deal-making is on the rise again and now is the time for biopharma companies to embrace M&As to prepare for future growth.

A remarkable run indeed, but cost questions can’t be ignored.

What are the reasons behind the slump and what does the future hold?

The recent flurry of Q1 earnings reports offer a unique opportunity to assess the real-time impacts of COVID-19 on the sector.

With a new Chinese pharma or biotech company listing on either the HKEX or STAR exchange in China almost every week, it is important consideration US pharma and biotech companies to have a focused China market strategy, writes Enoch Kariuki.

Adding context to Pfizer’s orbit-busting, first-quarter earnings.

The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?

Report provides comprehensive look at financial and accounting issues faced by life sciences industry.

Examining the key biopharma stock numbers and industry trends from a year that challenged the conduct of business and market stability like never before.

Amid vaccine heroics, its complex story may finally be resonating.

Dueling paths leave market fortunes uncertain.